Advertisement

Topics

HER2-positive breast cancer is lost in translation: time for patient-centered research

05:34 EDT 2 Aug 2017 | Nature Publishing

The development of predictive biomarkers is complex and the non-systematic approach to biomarker development in HER2-positive breast cancer challenges the way translational research is performed. Women with very favourable prognostic features will likely prefer shorter courses of treatment and might enquire about the possibility to forego aggressive chemotherapy. Considering these legitimate needs, Gingras et al. review the results of more than a decade of translational research efforts in this disease.

Original Article: HER2-positive breast cancer is lost in translation: time for patient-centered research

NEXT ARTICLE

More From BioPortfolio on "HER2-positive breast cancer is lost in translation: time for patient-centered research"

Quick Search
Advertisement
 

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...